CLINICAL_TRIALS trial_result · 2018-04-10

Clinical Trial Update: Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR [Phase 2]

Phase 2 study of luminespib (AUY922) in non-small cell lung cancer with EGFR exon 20 insertion mutations has completed. Results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Massachusetts General Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-04-10